Liver Fibrosis and Antiretroviral Therapy | Zendy

Jade Ghosn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Liver Fibrosis and Antiretroviral Therapy

Author(s) -

Jade Ghosn

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/499060

Subject(s) - medicine , hepatitis c virus , liver disease , hepatitis c , human immunodeficiency virus (hiv) , disease , immunology , cause of death , antiretroviral therapy , fibrosis , virus , viral load

patients are coinfected with hepatitis C virus (HCV). Since the introduction of combined HAART regimens, liver disease has emerged as an important cause of death among people living with HIV infection, especially among HIV-HCVcoinfected patients [1]. Complications of HCV-related liver disease are the leading cause of hospitalization and death among people living with HIV infection [2]. Indeed, as was previously reported in Clinical Infectious Diseases, the progression of liver fibrosis is accelerated in HIV-HCV-

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research